OKYO Pharma Limited Director/PDMR Shareholding (3024K)

TIDMOKYO

RNS Number : 3024K

OKYO Pharma Limited

01 September 2021

OKYO Pharma Limited

("OKYO" or the "Company")

Grant of options - Director dealings

London, 1 September, 2021 - OKYO Pharma Limited (LSE: OKYO) ("OKYO" or the "Company"), the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce , announces that the board of directors of the Company (the "Board" or "Directors"), with Mr Brancaccio absenting himself on grounds of interest, has awarded the following options on 31 August 2021.

(a) Gary Jacob

Mr Jacob has been awarded options to acquire 13,000,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company's shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.

Keeren Shah

Ms Shah has been awarded options to acquire 500,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company's shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.

(b) John Brancaccio

Mr Brancaccio has been awarded options to acquire 900,000 ordinary shares in the capital of the Company. The options are exercisable at a price of 4.9 pence per share (being the mid-market closing price of the Company's shares traded on the LSE on 31 August 2021). The options will vest in equal tranches over four years beginning on the date of grant.

This information set out below is provided in accordance with Article 19(3) of EU Regulation 596/2014.

 
 1.   Details of PDMR / person closely associated 
 a)   Name                (i) Gary Jacob 
                           (ii) Keeren Shah 
                           (iii) John Brancaccio 
     ------------------  -------------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------- 
 a)   Position            (i) Chief Executive Officer 
       / status            (ii) Chief Financial Officer 
                           (iIi) Non-Executive Director 
     ------------------  -------------------------------------------- 
 b)   Initial             Initial notification 
       notification 
       /amendment 
     ------------------  -------------------------------------------- 
 3.   Details of the issuer 
     ---------------------------------------------------------------- 
 a)   Name                OKYO Pharma Limited 
     ------------------  -------------------------------------------- 
 b)   LEI                 213800VVN5CB56Y15A05 
     ------------------  -------------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ---------------------------------------------------------------- 
 a)   Description         Ordinary Shares of no par value 
       of the 
       financial 
       instrument 
     ------------------  -------------------------------------------- 
 b)   Identification      ISIN for OKYO Pharma Limited: GG00BD3FV870 
       code of 
       the Financial 
       Instrument 
     ------------------  -------------------------------------------- 
 c)   Nature              Grant of options 
       of the 
       transaction 
     ------------------  -------------------------------------------- 
 d)   Price(s)            Price      Volume 
       and volume(s)       (i) 4.9p   (i) 13,000,000 
                           (ii) 4.9p  (ii) 500,000 
                           (iii) 4.9p (iii) 900,000 
     ------------------  -------------------------------------------- 
 f)   Date of             31 August 2021 
       the transaction 
     ------------------  -------------------------------------------- 
 
 g)   Place of            XLON 
       the transaction 
     ------------------  -------------------------------------------- 
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

 
OKYO Pharma Limited         Willy Simon    [phone] 
Optiva Securities Limited   Robert Emmet   + 44 (0)20 3981 4173 
 

For further information, please visit the Company's website at www.okyopharma.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKFLFXFVLLBBX

(END) Dow Jones Newswires

September 01, 2021 02:00 ET (06:00 GMT)